| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.09 |
| mRNA | Bryostatin 1 | FIMM | pan-cancer | AAC | -0.25 | 0.09 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.069 | 0.09 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.09 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.058 | 0.09 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.061 | 0.1 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.1 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.064 | 0.1 |